BioLargo Amends 10-K to Disclose Executive Compensation, Related Party Deals, and CFO Compliance Lapse

summarizeSummary

BioLargo filed an amended 10-K to include previously omitted details on executive compensation, insider ownership, related party transactions, and a compliance lapse by the CFO.

check_boxKey Events

• Executive Compensation Details Revealed

  The company disclosed executive compensation for 2024 and 2025, showing that a substantial portion of compensation for the CEO and CSO involved accepting shares in lieu of cash, and the CFO received no cash compensation, only options. For 2025, the CFO was awarded options with an aggregate fair value of $217,962.

• Material Related Party Transactions with CEO

  CEO Dennis P. Calvert invested a total of $241,000 in the partially-owned subsidiary Clyra Medical through secured promissory notes and warrants across three transactions (October 2024, May 2025, March 2026). BioLargo, Inc. guaranteed the payment of these notes, exposing the parent company to potential liability.

• CFO Failed to Disclose Option Awards

  The filing revealed that CFO Charles K. Dargan II failed to timely disclose an option issued upon annual renewal of his agreement and another option issued on September 30, 2025, representing a compliance lapse.

• Insider Ownership Updated

  As of April 30, 2026, the Chief Science Officer, Kenneth R. Code, is the largest beneficial owner with 7.6% of outstanding shares, while CEO Dennis P. Calvert holds 4.3%. All directors and officers as a group beneficially own 19.3% of the company's common stock.

auto_awesomeAnalysis

This 10-K/A filing provides crucial Part III information (executive compensation, security ownership, related party transactions, and accounting fees) that was omitted from the original 10-K filed on March 4, 2026. The disclosures reveal that a significant portion of executive and director compensation is equity-based, reflecting a strategy to conserve cash but also leading to potential dilution. Notably, the CEO engaged in material related party transactions by investing in a subsidiary (Clyra Medical) with BioLargo guaranteeing the notes, which introduces potential conflicts of interest and additional risk for the parent company. Furthermore, the CFO failed to timely disclose certain option awards, indicating a lapse in corporate governance and compliance. These details offer a more complete, albeit mixed, picture of the company's financial commitments and governance practices.